Follow the Knight Therapeutics Inc. stock price and the full directors' dealings record of the company, a listed issuer based in Canada. Shares are quoted on the CA market, under the oversight of SEDI. Market capitalisation: €964.6m. The latest transaction was disclosed on 15 July 2026 (51 - Exercise of options). Among the most active insiders: Groleau, Melanie. Every trade is openly available.
43
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Knight Therapeutics Inc. Strong Buy (bullish), based on 7 analysts. Average price target: CA$10.83.
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,759 of 29,064 companies
42.6
score / 100
Value
40
Quality
45
FCF yld3.8%
Earn yld-0.6%
EV/EBITDA16.7x
ROE1.9%
Gross mgn44%
Net mgn-1.2%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
5,129 shares@ CA$9.250.0049% mcap4.1% of flowCommon SharesTSXSEDI:4733880
Canonical exit: 8 Sept 2026 (T+90)
25 of 43 declarations
Acerca de Knight Therapeutics Inc.
Knight Therapeutics Inc. es una empresa farmacéutica canadiense centrada en la adquisición y desarrollo de medicamentos para los mercados canadiense e internacional. Cotiza en la Bolsa de Valores de Toronto bajo el símbolo KNT.